GSA Capital Partners LLP lowered its stake in shares of Biomea Fusion, Inc. (NASDAQ:BMEA – Free Report) by 36.8% during the third quarter, according to the company in its most recent disclosure with ...
Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed. So, the natural question for Biomea Fusion (NASDAQ:BMEA) ...
On Thursday, Biomea Fusion Inc (BMEA) stock saw a decline, ending the day at $9.37 which represents a decrease of $-0.97 or -9.38% from the prior close of $10.34. The stock opened at $10.46 and ...
REDWOOD CITY, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and ...
On Thursday, Piper Sandler adjusted its outlook on Biomea Fusion Inc. (NASDAQ:BMEA), increasing the price target to $19.00, up from the previous $10.00, while maintaining an Overweight rating on the ...
Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Biomea Fusion (BMEA – Research Report), retaining the price target ...
Barclays analyst Peter Lawson raised the firm’s price target on Biomea Fusion (BMEA) to $11 from $9 and keeps an Equal Weight rating on ...
REDWOOD CITY, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback